Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Clarksterh	10/14/2004 1:59:02 PM
	Read Replies (1) of 1386

Hi all – I am considering investing in PARS, but have some questions that perhaps some of y’all can help with: 1) I cannot find a really good writeup of the Complete Phase II TBI results (or even the partial Phase II results). The best I can find is the press release on this board from 2000 (all the press releases older than 2001 are no longer on the Pharmos site) 2) From the writeup that I could find it is apparent that the GOS score for the entire treatment group at 6 months is not much better than the placebo group. But the GOAT scores were. And yet they are using GOS (not GOAT) at 6 months in their Phase III. What’s up with that? Did they ever provide an explanation about why the GOS scores were not better in the treatment group? 3) Is there any analysis of the GCS>6 group? The effectivity in the GCS<=6 looks great, and the company focuses on it extensively, but it would be interesting to look at the remainder. Is there still any effectivity? Is the Phase III designed adequately to pick it up? Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next